Skip to main content



) --

Pharmacyclics Incorporated



) hit a new 52-week high Monday as it is currently trading at $48.60, above its previous 52-week high of $48.57 with 451,799 shares traded as of 11:10 a.m. ET. Average volume has been 852,100 shares over the past 30 days.

Pharmacyclics has a market cap of $3.25 billion and is part of the

health care

sector and


industry. Shares are up 217.1% year to date as of the close of trading on Friday.

TheStreet Recommends

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on discovering, developing, and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The company has a P/E ratio of 213.6, below the average drugs industry P/E ratio of 235 and above the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

TheStreet Ratings rates Pharmacyclics as a


. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, premium valuation and weak operating cash flow. You can view the full

Pharmacyclics Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center